Clinical trial

Immune system

Meningococcal disease

Meningococcal vaccine

Immunization

Bacteria

Biology

Meta-analysis

Neisseria meningitidis

Booster dose

Internal medicine

Pediatrics

Immunogenicity

Immunology

Genetics

Medicine

The Lancet Infectious Diseases

4CMenB has an acceptable short-term safety profile. The primary course is sufficient to achieve a satisfactory immune response within 30 days of vaccination. A booster dose is required for children to prolong the protection against strain M10713, and the long-term immunogenicity against strain NZ98/254 remains suboptimal.

Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis